CN110638996B - 一种促进胰岛再生降糖复合物及其制备方法和用途 - Google Patents
一种促进胰岛再生降糖复合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN110638996B CN110638996B CN201911058123.XA CN201911058123A CN110638996B CN 110638996 B CN110638996 B CN 110638996B CN 201911058123 A CN201911058123 A CN 201911058123A CN 110638996 B CN110638996 B CN 110638996B
- Authority
- CN
- China
- Prior art keywords
- extract
- islet
- promoting
- preparation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 70
- 239000008280 blood Substances 0.000 title claims abstract description 70
- 230000001737 promoting effect Effects 0.000 title claims abstract description 35
- 230000008929 regeneration Effects 0.000 title claims abstract description 33
- 238000011069 regeneration method Methods 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims description 27
- 239000008103 glucose Substances 0.000 title claims description 27
- 230000001603 reducing effect Effects 0.000 title abstract description 24
- 150000001875 compounds Chemical class 0.000 title abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 38
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 28
- 244000045195 Cicer arietinum Species 0.000 claims abstract description 20
- 235000010523 Cicer arietinum Nutrition 0.000 claims abstract description 20
- 241000208253 Gymnema sylvestre Species 0.000 claims abstract description 19
- 244000302512 Momordica charantia Species 0.000 claims abstract description 18
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 18
- 244000250129 Trigonella foenum graecum Species 0.000 claims abstract description 18
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims abstract description 18
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims abstract description 18
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 14
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 9
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 9
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 9
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 8
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 8
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 8
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 8
- 235000020230 cinnamon extract Nutrition 0.000 claims abstract description 8
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 8
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 7
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 7
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 7
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 7
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 7
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 7
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 7
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 7
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 7
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 7
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 7
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 7
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 7
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 7
- 235000008397 ginger Nutrition 0.000 claims abstract description 7
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 92
- 102000004877 Insulin Human genes 0.000 claims description 46
- 108090001061 Insulin Proteins 0.000 claims description 46
- 229940125396 insulin Drugs 0.000 claims description 46
- 210000004153 islets of langerhan Anatomy 0.000 claims description 25
- 239000003472 antidiabetic agent Substances 0.000 claims description 12
- 239000002243 precursor Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 244000241838 Lycium barbarum Species 0.000 claims description 7
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 7
- 235000015468 Lycium chinense Nutrition 0.000 claims description 7
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims description 4
- 241000549954 Gymnema yunnanense Species 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims 6
- 229940002508 ginger extract Drugs 0.000 claims 3
- 235000020708 ginger extract Nutrition 0.000 claims 3
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 230000009707 neogenesis Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 34
- 230000006378 damage Effects 0.000 abstract description 12
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 6
- 235000012754 curcumin Nutrition 0.000 abstract description 5
- 229940109262 curcumin Drugs 0.000 abstract description 5
- 239000004148 curcumin Substances 0.000 abstract description 5
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 45
- 230000006870 function Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 210000004923 pancreatic tissue Anatomy 0.000 description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 210000002919 epithelial cell Anatomy 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 11
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 10
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 10
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 9
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000002660 insulin-secreting cell Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- 229930191576 Biochanin Natural products 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000020828 fasting Nutrition 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 241001092040 Crataegus Species 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000000277 pancreatic duct Anatomy 0.000 description 5
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000011506 response to oxidative stress Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- -1 lipid free radical Chemical class 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 description 1
- 235000020927 12-h fasting Nutrition 0.000 description 1
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102100031250 Disks large-associated protein 1 Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 241000208251 Gymnema Species 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 101000731000 Homo sapiens Membrane-associated progesterone receptor component 1 Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229930185803 charantin Natural products 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 210000002797 pancreatic ductal cell Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种促进胰岛再生降糖复合物及其制备方法和用途。包括鹰嘴豆或鹰嘴豆提取物，α‑硫辛酸，L‑牛磺酸，肉桂或肉桂提取物，枸杞或枸杞提取物，苦瓜或苦瓜提取物，胡芦巴或胡芦巴乙醇提取物，匙羹藤或匙羹藤提取物，生姜或姜黄素，山楂或山楂提取物。所述促进胰岛再生降糖复合物采用安全有效的药食两用食材、可保护糖尿病患者胰岛功能，减缓其功能降低或破坏，并促进胰岛再生,达到降低血糖的目的。
Description
技术领域
本发明涉及糖尿病组方领域，尤其涉及一种促进胰岛再生降糖复合物及其制备方法和用途。
背景技术
糖尿病(Diabetes mellitus，DM)是一组由遗传因素、环境因素及其相互作用而引起的，因胰岛素分泌缺陷和(或)作用缺陷而导致的以血糖升高为主要特征的一种综合性代谢疾病。根据糖尿病联盟(IDF)2017年统计，全球18岁以上成年人糖尿病患者呈逐年增加的趋势，2017年已达4.24亿。同样根据该报告，我国糖尿病患者也已达到1.14亿。糖尿病及其并发症为患者带来痛苦，为患者家庭带来严重经济负担。
根据发病机理不同，糖尿病可分为1型、2型、其他类型糖尿病及妊娠期糖尿病。1型糖尿病患者是由于机体自身免疫系统攻击并破坏胰岛β-细胞，致使胰岛素生成不足而导致高血糖，属自身免疫性疾病，约占糖尿病患者总数的5％左右；而2型糖尿病(T2DM)可由胰岛素分泌缺陷或胰岛素敏感性下降所致，是主要糖尿病类型，约占糖尿病患者总数的90％左右；其他类型糖尿病主要是指某些单基因突变所致或未知原因所致的糖尿病，约占糖尿病患者总数的1-2％；妊娠期糖尿病是在妇女妊娠期发现或首次诊断的糖耐量异常的疾病，约占糖尿病患者总数的2-3％左右。该型患者妊娠期结束后约有30％可恢复正常，其余70％可发展成为2型糖尿病。可见2型是糖尿病的主要类型，阐明其机理将有助于开发治疗糖尿病的个体化药物。
目前临床使用的各种降糖药物，包括胰岛素及其类似物，以及各种口服降糖药以控制血糖为目的，属对症治疗，无法治愈。随着用药时间以及病程延长，最终会导致分泌胰岛素的胰岛beta-细胞功能下降、丧失，最终导致胰岛细胞数量减少，进一步使得糖尿病症状加剧，引起各种糖尿病并发症，危机患者生命。
为了修复受损的胰岛beta-细胞，延缓病程，延缓糖尿病患者的并发症产生。已有一些专利申请文件宣称具有保护胰岛，使其功能恢复。这些专利申请包括三例多肽或蛋白制剂(专利公开号分别为：CN 1723034A，CN 1615150A，CN 1729016A)以及三例中草药复方制剂(专利公开号分别为A61K 35/78，CN 106511840 A，CN 107456532 A)。这些专利申请文件中所提供的制剂或方案存在以下问题：1)使用不方便，如多肽或蛋白制剂，不能口服，如果应用于临床需要长期注射给药；2)疗效不明确；3)无论是多肽还是中药复方制剂均属于药品，长期服用必然会对机体产生不良反应，甚至毒性作用。
发明内容
本发明的目的在于提供一种含有药食两用食材、可保护糖尿病患者胰岛功能，减缓其功能降低或破坏，并促进其再生的安全有效的促进胰岛再生的促进胰岛再生降糖复合物。
为实现上述目的，促进胰岛再生的降糖复合物，其特征在于，包括鹰嘴豆或鹰嘴豆提取物，α-硫辛酸，L-牛磺酸，肉桂或肉桂提取物，枸杞或枸杞提取物，苦瓜或苦瓜提取物，胡芦巴或胡芦巴乙醇提取物，匙羹藤或匙羹藤提取物，生姜或姜黄素，山楂或山楂提取物。
进一步，所述鹰嘴豆或鹰嘴豆提取物：α-硫辛酸：L-牛磺酸：肉桂或肉桂提取物：枸杞或枸杞提取物：苦瓜或苦瓜提取物：胡芦巴或胡芦巴乙醇提取物：匙羹藤或匙羹藤提取物：生姜或姜黄素：山楂或山楂提取物的重量比为(10-40)：(1-5)：(1-5)：(5-10)：(10-30)：(5-10)：(10-15)：(10-15)：(5-10)：(10-20)。
进一步，所述鹰嘴豆或鹰嘴豆提取物：α-硫辛酸：L-牛磺酸：肉桂或肉桂提取物：枸杞或枸杞提取物：苦瓜或苦瓜提取物：胡芦巴或胡芦巴乙醇提取物：匙羹藤或匙羹藤提取物：生姜或姜黄素：山楂或山楂提取物的重量比为25：1：1：10：15：8：12：13：5：15。
进一步，将肉桂，枸杞，苦瓜，胡芦巴，匙羹藤，鹰嘴豆，生姜，山楂粉碎，过60-100目筛网；各成分中分别加入浓度为10-95％的食用乙醇，使固液重量比为1：(10-25)，进行超声后减压旋蒸，得到的固体粉末再与α-硫辛酸，L-牛磺酸混合即可。
进一步，所述超声的功率为400W，工作/间歇15s/3s，超声时间为10-30min，超声次数为1-3次。
本发明还保护所述促进胰岛再生降糖复合物的制备方法，其特征在于，将肉桂，枸杞，苦瓜，胡芦巴，匙羹藤，鹰嘴豆，生姜，山楂粉碎，过60-100目筛网；各成分中分别加入浓度为10-95％的食用乙醇，使固液重量比为1：(10-25)，进行超声后减压旋蒸，得到的固体粉末再与α-硫辛酸，L-牛磺酸混合即可。
进一步，所述超声的功率为400W，工作/间歇15s/3s，超声时间为10-30min，超声次数为1-3次。
本发明还保护该促进胰岛再生降糖复合物用于降低血糖、血脂，消除自由基，和/或保护胰岛免于氧化应激损伤，和/或促进胰腺前体细胞分化为具有胰岛素合成和分泌能力的胰岛细胞，的食物或药物的用途。
该促进胰岛再生降糖复合物用于控制血糖的食物或药物的用途。
所述鹰嘴豆特别是鹰嘴豆芽素单独不具有促进胰岛再生的功能，但和其它组分按一定比例配合制成复方制剂，可显著促进2型糖尿病小鼠胰岛beta-细胞功能恢复(图1)，促进具有胰腺前体细胞特性的胰腺导管上皮细胞分化为胰岛素分泌细胞(图3，图4)再生(只有复方+鹰嘴豆芽素处理小鼠的胰腺组织可被胰岛素特异性抗体以及胰腺导管上皮细胞特异性标志物—CK19共同染色)，并促使2型糖尿病小鼠血糖降低(图2)。目前以该配方制备的复合物可促进糖尿病小鼠受损的胰腺Beta-细胞前体细胞分化为胰岛素分泌细胞，促进胰腺Beta- 细胞功能恢复，从而达到降低血糖的目的，在国内外尚属首次。
糖尿病患者体内高糖、高脂的存在，可引起氧化应激反应、造成自由基对包括胰腺组织以及血管等组织器官损伤，进而会导致神经细胞死亡，引起糖尿病神经病变，使糖尿病症状加重，并进一步导致胰岛细胞的凋亡和结构、功能破坏。而配方中苦瓜或苦瓜提取物(苦味葫芦素和苦瓜甙)不仅有类似胰岛素的作用，而且还可以刺激胰岛素释放，同时可增加胰岛素敏感性，减少胰岛素抵抗，产生明显的降血糖作用。胡芦巴，又称大花紫薇，大花紫薇，俗称“巴拉巴(banaba)”，在东南亚地区属于药食两用植物。原产于亚洲热带。分布于印度、斯里兰卡、马来西亚、菲律宾和越南等地。在我国广东、广西、云南、海南及福建地区也有大量栽培。在菲律宾其叶制成的茶饮料被广泛用于治疗和预防糖尿病，被誉为“天然植物胰岛素”，口服有效且无副作用，能减轻体重却不影响食欲。胡芦巴或胡芦巴乙醇提取物(科罗索酸)不仅具有类似胰岛素的生理作用，刺激细胞膜的葡萄糖运输通道，增强细胞对葡萄糖的利用，进而降低血糖含量；同时还可以增加机体对胰岛素的敏感性，降低胰岛素抵抗。匙羹藤为萝藦科匙羹藤属植物匙羹藤的根或嫩枝叶。匙羹藤或匙羹藤提取物，可促进胰岛素释放，增加胰岛素的敏感性等功能，达到降低血糖、血脂的目的。苦瓜或苦瓜提取物、胡芦巴或胡芦巴乙醇提取物以及匙羹藤或匙羹藤提取物具有类似胰岛素样功能，它们联合使用可促进葡萄糖的吸收利用，可降低血糖，以减少高糖对胰岛细胞的破坏。生姜或其提取物姜黄素可降低高糖对神经组织，血管的损伤，并预防糖尿病引起的并发症，以维护神经体液对胰腺组织的正常生理功能。
L-牛磺酸促进肌肉细胞对葡萄糖和氨基酸的利用，加速糖酵解，增加糖原异生，降低糖尿病患者的餐后血糖负荷，使餐后血糖降低。肉桂或肉桂提取物以及山楂或山楂提取物(山楂叶总黄酮)可调节脂质代谢，降低血液中总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)，并提高SOD、CAT活性，减少脂质自由基产生。α-硫辛酸是一种水溶性和脂溶性代谢“超级抗氧化剂”，可以清除机体的自由基，减弱氧化应激，保护胰岛细胞免于氧化应激和破坏。枸杞或枸杞提取物抗氧化，降低自由基，保护胰岛细胞的功能。L-牛磺酸、肉桂或肉桂提取物，山楂或山楂提取物，α-硫辛酸以及枸杞或枸杞提取物共同作用，可消除自由基，降低高血糖、高脂所致的氧化应激反应，保护胰岛免于氧化应激损伤。
上述各成分 联合使用可降低血糖、血脂，消除自由基，降低高血糖、高脂所致的氧化应激反应，保护胰岛免于氧化应激损伤，从而减少高糖、高脂对胰岛组织的破环，为鹰嘴豆特别是鹰嘴豆芽素发挥促进胰腺前体细胞分化为具有胰岛素合成和分泌能力的胰岛细胞创造条件，进而可促进胰腺前体细胞分化为胰岛素分泌细胞，响应血糖升高后，刺激胰岛素分泌，达到控制血糖的目的。
采用该技术生产的保健品，服用方便，而且各种原材料均属于药食两用的食材，所以由其提取物制备的保健品安全性高，在本发明的实验体系中获得了明确的实验证据。
附图说明
图1是实施例1中治疗前、后各组小鼠胰腺Beta-细胞功能(HOMA-B)结果图(Mean±SEM, *P<0.05同组小鼠治疗后和治疗前相比)。
图2是实施例1中各组对2型糖尿病小鼠血糖的影响结果图(Mean±SEM,*P<0.05与模型组小鼠相比)。
图3是实施例1各组小鼠的胰腺组织H&E染色，观察胰岛数量及其形态结果图。
图4是实施例1各组小鼠的胰腺组织免疫荧光染色，观察分泌胰岛素的胰岛细胞团与具有CK19标志物的胰腺导管上皮细胞共定位结果图。
具体实施方式
下面详细描述本发明的实施例，所述实施例的示例在附图中示出，其中自始至终相同或类似的标号表示相同或类似的元件或具有相同或类似功能的元件。下面通过参考附图描述的实施例是示例性的，旨在用于解释本发明，而不能理解为对本发明的限制。实施例中未注明具体技术或条件者，按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者，均为可以通过市购获得的常规产品。
实施例1：促进胰岛再生降糖复合物的制备及其效果验证
原材料：见表1。
制备方法：α-硫辛酸，L-牛磺酸采用食品级市售产品。将肉桂，枸杞，苦瓜，胡芦巴，匙羹藤，鹰嘴豆，生姜，山楂，粉碎，过60-100目筛网。各成分中分别加入浓度为10-95％的食用乙醇，固液重量比为1：10-25，超声功率为400W，工作/间歇15s/3s，超声时间为10-30min，超声次数为1-3次，60℃减压旋蒸，得固体粉末。将固体粉末按比例混合。可制成胶囊制剂便于服用。
表1实施例1-5各原材料用量表
效果验证试验:
利用高糖、高脂结合小剂量STZ诱导的小鼠2型糖尿病模型对实施例1进行了验证。其具体实验流程和数据如下：
一、[实验目的]
利用高糖、高脂饲料结合小剂量STZ诱导2型糖尿病小鼠模型，观察实施例1所得促进胰岛再生降糖复合物对2型糖尿病小鼠的胰岛再生及降糖效果。
二、[实验原理]
实施例1所得促进胰岛再生降糖复合物可降低血糖、血脂，消除自由基，降低高血糖、高脂所致的氧化应激反应，保护胰岛免于氧化应激损伤，从而减少高糖、高脂对胰岛组织的破环，将为鹰嘴豆特别是鹰嘴豆芽素发挥促进胰腺前体细胞分化为具有胰岛素合成和分泌能力的胰岛细胞创造条件，进而达到促进胰腺前体细胞分化为胰岛素分泌细胞，以相应血糖升高，分泌胰岛素，达到控制血糖的目的。
三、[实验材料]
1、实验动物
雄性C57BL/6J小鼠，3-4周龄，体重15-20g(上海斯莱克实验动物有限责任公司)。
2、实验器材
实验仪器：血糖测试仪、血糖试条(三诺生物传感股份有限公司)、pH计(sartorius， PB-10)，离心机(eppendorf centrifuge 5424R)、电子天平(METTLER TOLEDOAL204)，掌上离心机(厦门市宝能科技有限公司)。
实验材料：HFD45高糖、高脂饲料(戴茨生物科技有限公司)，Streptozocin(Aladin，LOT F1714058)、一水合柠檬酸(西陇化工股份有限公司)、柠檬酸三钠(汕头市达濠精细化学品公司)，Ultra sensitive mouse insulin immunoassay kit(MLT180)，玉米芯垫料(货号：1060003，江苏省协同医药生物工程有限责任公司)，清洁级实验鼠维持饲料(货号： 1010001，江苏省协同医药生物工程有限责任公司)，羧甲基纤维素钠(阿拉丁LOT#C1616016)、Eppendof管、无菌注射器(康友一次性使用无菌注射器，带针，无菌，无热原，1mL)、凯丰电子秤、一次性乳胶手套(shanghai ammex corporation)。
四、[实验方法]
1、高脂饲料诱导脂代谢紊乱模型
雄性C57/B6小鼠过渡性饲养后，采用HFD45高脂饲料饲养7～8周，取小鼠尾血测血糖及胰岛素含量。
2、STZ诱导2型糖尿病
(1)柠檬酸缓冲液及STZ溶液的配制
柠檬酸(分子量：210.14)2.1g加入双蒸水100mL中配成A液。
柠檬酸钠(分子量：294.10)2.94g加入双蒸水100mL中配成B液。
用时将A、B液按体积比1：1混合，由PH计测定pH值，调节pH＝4.2-4.5，即柠檬酸缓冲液。
STZ溶液配置：临注射前，准确称取5.5mg STZ，溶于1mL上述柠檬酸缓冲液中，配置成5.5mg/mL的STZ溶液。
(2)STZ诱导及发病
HFD45高脂饲料喂养57d后禁食12h，于58d开始按30mg/kg注射STZ溶液，连续注射3d，每次注射结束后2h再给于HFD45高脂饲料喂养。注射STZ两周之后，取小鼠尾血检测血糖及胰岛素含量。
3、降糖效果考察
选取造模成功的小鼠25只，分为5组，分别为：
组1：(空白对照组):选取未造模的正常同窝小鼠5只，只灌胃给于生理盐水。
组2:(模型组，即溶剂对照组)：只灌胃给于生理盐水。
组3：(阳性对照组，也即利拉鲁肽组)：180ug/kg/天，腹腔注射。
组4：(组方组)：在实施例1所制备得到的促进胰岛再生降糖复合物基础上去掉鹰嘴豆芽素粗提物成分，用生理盐水制备成17.4mg/mL的混悬液，灌胃体积为0.1mL/10克小鼠体重,灌胃剂量为174mg/kg。
组5：(鹰嘴豆芽素组)：鹰嘴豆芽素，用生理盐水制备成0.8mg/mL的混悬液，灌胃体积为0.1mL/10克小鼠体重,灌胃剂量为8mg/kg/天。
组6：(组方+鹰嘴豆芽素组，又叫治疗组)：实施例1所得促进胰岛再生降糖复合物，用生理盐水制备成18.2mg/mL的混悬液，灌胃体积为0.1mL/10克小鼠体重,每天灌胃给于174mg/kg组方+8mg/kg鹰嘴豆芽素粗提物。
按照上述分组，治疗动物，连续十周。期间于每周测定小鼠的随机血糖、体重，并于第十周时测小鼠空腹血糖、取小鼠尾血，测定胰岛素含量，以下述公式计算HOMA-B，HOMA-B＝ (20*FINS)/(FPG-3.5)，(其中FINS为空腹胰岛素，FPG为空腹血糖)。并取小鼠心脏、肝脏、脾脏、肺脏、肾脏做H&E染色以评估毒性，取胰腺组织做H&E、免疫荧光。
五、[实验结果]
1、实施例1所得促进胰岛再生降糖复合物可显著促进小鼠受损的胰岛beta-细胞功能，从而使小鼠血糖显著降低。
每天灌胃给予(灌胃体积为：0.1mL/10克小鼠体重)上述6组小鼠，连续灌胃10周。每周测一次随机血糖。实验开始前及实验结束时测空腹血糖和胰岛素含量，并计算胰岛功能 (HOMA-B)。结果如图1、图2所示，在开始治疗前，与空白对照组(组1)相比，各组小鼠胰岛Beta-细胞功能均显著下降(图1)；各组小鼠血糖均上升(图2)。
各组小鼠治疗后，阳性对照组(图2，组3)——利拉鲁肽治疗一周即可使小鼠血糖显著下降，其后一直维持在与空白对照组小鼠血糖相同水平。不含鹰嘴豆芽素的(图2，组4)的小鼠血糖有所下降，但与模型组(图2，组2)相比，不显著；单独鹰嘴豆芽素治疗小组 (图2，组5)，与模型组(图2，组2)相比，小鼠血糖没有显著下降；而实施例1治疗组 (图2，组6)在治疗第四周以后，血糖即开始逐渐下降，到第八周时达到与利拉鲁肽组(涂，组3)相近水平。此时，与模型组(图2，组2)相比，实施例1治疗组(图2，组6)小鼠胰岛Beta-细胞功能显著增强(图1，组6)，血糖明显下降(图2，组6)。
上述结果表明实施例1所得的可显著促进已经受损的小鼠胰腺Beta-细胞功能恢复，从而降低2型糖尿病小鼠血糖。
2、实施例1所得促进胰岛再生降糖复合物可显著促进2型糖尿病小鼠受损的胰岛Beta- 数量增加。
为了进一步观察上述2型糖尿病小鼠胰岛Beta-细胞功能增加是否与增加小鼠胰岛数量有关。申请人对各组小鼠的胰腺组织进行了H&E染色，结果如图3所示。图3为各组小鼠的胰腺组织H&E染色，观察胰岛数量及其形态结果图。空白对照组(组1)小鼠胰腺组织内胰岛数量较多，胰岛形态完整。模型组(组2)小鼠胰腺组织内胰岛数量很少，胰岛形态不完整。利拉鲁肽组(组3)，组方组(组4)，以及鹰嘴豆芽素组(组5)单独治疗组小鼠胰腺组织内胰岛数据量均减少，胰岛形态不完整。而实施例1配方治疗组(组6)胰岛数量增加，形态完整，而且主要分布于胰腺导管周围。
3、实施例1所得促进胰岛再生降糖复合物可显著促进2型糖尿病小鼠胰腺导管细胞分化为胰岛素分泌细胞。
为了进一步观察，实施例1治疗组小鼠胰腺组织中新生的胰岛是否由胰岛前体细胞/胰腺导管上皮细胞分化而来,申请人利用胰腺导管上皮细胞特异性标志物——CK19对胰腺导管上皮细胞进行追踪，对各组小鼠胰腺组织同时进行胰岛素免疫荧光染色。结果如图4所示，图4为实施例1各组小鼠的胰腺组织免疫荧光染色图。其中DAP1为细胞核染料，可对细胞核进行染色，insulin为胰岛素染色，如果是阳性染色表示为具有合成和分泌胰岛素能力的胰岛细胞；CK19为胰腺导管上皮血细胞特异性标志物，可用CK19对胰腺导管上皮细胞进行追踪；Merge为胰岛素(Insulin)染色图和CK19染色图叠加，如果两者可叠加，则表示观测对象区域内同时存在胰腺导管上皮细胞和胰岛素分泌细胞；空白对照组(组1)，小鼠胰岛细胞可被胰岛素抗体特异性染色，显示胰岛形态完整，胰腺导管上皮细胞则可被CK19染色，但未观察到CK19和胰岛素染色重叠的现象。表明在正常小鼠中很少会见到胰腺导管上皮细胞分化为胰岛素分泌细胞的现象。而模型组(组2)，利拉鲁肽组(组3)，组方组(组4)以及鹰嘴豆芽素组(组5)单独治疗组，小鼠胰岛细胞胰岛素染色均较浅，形态不完整。表明造模后各组小鼠胰腺组织中胰岛受到破坏。上述各组均可见到胰腺导管细胞可被CK19染色，表明染色的特异性。但均未观察到CK19和胰岛素染色共定位的现象。表明，这些处理均未出现胰腺导管上皮细胞分化为胰岛素分泌细胞的现象。然而在组方+鹰嘴豆芽素治疗组(即组6)，小鼠胰腺组织胰岛beta-细胞胰岛素染色也较浅，形态不完整。表明造模后小鼠的胰岛均受损。但在这一组治疗小鼠的胰腺组织中观察到很多可被胰岛素以及CK19共同染色的异染色质灶。表明，实施例1所得促进胰岛再生降糖复合物可促进具有胰腺前体细胞特性的胰腺导管上皮细胞分化为胰岛素阳性的胰岛样细胞团。
综上所述，上述研究表明，实施例1所得促进胰岛再生降糖复合物可促进具有胰腺前体细胞特性的胰腺导管上皮细胞分化为胰岛素阳性的胰岛样细胞团(图4)，使得胰岛数目增多，形态恢复。该胰岛样细胞团具有分泌胰岛素的功能，可使小鼠胰岛功能恢复(图1)，从而使得小鼠血糖下降(图2)。
事实病案举例：
李某某，男，51岁，福建厦门人。2005年，确诊患有2型糖尿病，服用实施例1所得促进胰岛再生降糖复合物前，体型偏胖，面色黄白，口渴多饮，乏力。空腹血糖12-14mM，随机血糖18-20mM。2019年初服“实施例1所得促进胰岛再生降糖复合物”胶囊(1.4克/ 每日，每日晚间服用一次，连续服用60天)。两月后糖尿病针状缓解，有力，口不渴，查空腹血糖为6-8mM，随机血糖9-12mM。
上述结果表明实施例1所得促进胰岛再生降糖复合物对2型糖尿病小鼠或2型糖尿病患者均可达到降糖效果，其机理在于通过促进患者胰腺导管上皮细胞分化为胰岛素分泌细胞而发挥作用。
实施例2：促进胰岛再生降糖复合物的制备
原材料：见表1。
制备方法：同实施例1。
效果同实施例1。
实施例3：促进胰岛再生降糖复合物的制备
原材料：见表1。
制备方法：同实施例1。
效果同实施例1。
实施例4：促进胰岛再生降糖复合物的制备
原材料：见表1。
制备方法：同实施例1。
效果同实施例1。
实施例5：促进胰岛再生降糖复合物的制备
原材料：见表1。
制备方法：同实施例1。
效果同实施例1。
尽管上面已经示出和描述了本发明的实施例，可以理解的是，上述实施例是示例性的，不能理解为对本发明的限制，本领域的普通技术人员在不脱离本发明的原理和宗旨的情况下在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (7)
1.一种促进胰岛再生降糖复合物，其特征在于，由鹰嘴豆提取物，α-硫辛酸，L-牛磺酸，肉桂提取物，枸杞提取物，苦瓜提取物，胡芦巴乙醇提取物，匙羹藤提取物，生姜提取物，山楂提取物组成；
其制备方法为：将肉桂，枸杞，苦瓜，胡芦巴，匙羹藤，鹰嘴豆，生姜，山楂粉碎，过60-100目筛网；各成分中分别加入浓度为 10-95%的食用乙醇，使固液重量比为 1：（10-25），进行超声后减压旋蒸，得到的固体粉末再与α-硫辛酸，L-牛磺酸混合即可；
所述鹰嘴豆提取物：α-硫辛酸：L-牛磺酸：肉桂提取物：枸杞提取物：苦瓜提取物：胡芦巴乙醇提取物：匙羹藤提取物：生姜提取物：山楂提取物的重量比为（10-40）：（1-5）：（1-5）：（5-10）：（10-30）：（5-10）：（10-15）：（10-15）：（5-10）：（10-20）。
2.如权利要求1所述促进胰岛再生降糖复合物，其特征在于，所述鹰嘴豆提取物：α-硫辛酸：L-牛磺酸：肉桂提取物：枸杞提取物：苦瓜提取物：胡芦巴乙醇提取物：匙羹藤提取物：生姜提取物：山楂提取物的重量比为25：1：1：10：15：8：12：13：5：15。
3.如权利要求1所述促进胰岛再生降糖复合物，其特征在于，所述超声的功率为 400W，工作/间歇 15 s/3s ，超声时间为 10-30 min，超声次数为 1-3 次。
4.一种权利要求1-2任一所述促进胰岛再生降糖复合物的制备方法，其特征在于，将肉桂，枸杞，苦瓜，胡芦巴，匙羹藤，鹰嘴豆，生姜，山楂粉碎，过60-100目筛网；各成分中分别加入浓度为 10-95%的食用乙醇，使固液重量比为 1：（10-25），进行超声后减压旋蒸，得到的固体粉末再与α-硫辛酸，L-牛磺酸混合即可。
5.如权利要求4所述制备方法，其特征在于，所述超声的功率为 400 W，工作/间歇 15s/3s ，超声时间为 10-30 min，超声次数为 1-3 次。
6.如权利要求1-3任一所述促进胰岛再生降糖复合物用于制备降低血糖，和/或制备促进胰腺前体细胞分化为具有胰岛素合成和分泌能力的胰岛细胞，的药物的用途。
7.如权利要求1-3任一所述促进胰岛再生降糖复合物用于制备控制血糖的药物的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911058123.XA CN110638996B (zh) | 2019-11-01 | 2019-11-01 | 一种促进胰岛再生降糖复合物及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911058123.XA CN110638996B (zh) | 2019-11-01 | 2019-11-01 | 一种促进胰岛再生降糖复合物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110638996A CN110638996A (zh) | 2020-01-03 |
| CN110638996B true CN110638996B (zh) | 2022-07-15 |
Family
ID=68995397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911058123.XA Active CN110638996B (zh) | 2019-11-01 | 2019-11-01 | 一种促进胰岛再生降糖复合物及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110638996B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109745359A (zh) * | 2019-03-08 | 2019-05-14 | 储殷 | 有利于保持血糖平衡和预防糖尿病及其并发症的组合物及其制备方法 |
-
2019
- 2019-11-01 CN CN201911058123.XA patent/CN110638996B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109745359A (zh) * | 2019-03-08 | 2019-05-14 | 储殷 | 有利于保持血糖平衡和预防糖尿病及其并发症的组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110638996A (zh) | 2020-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kassaian et al. | Effect of fenugreek seeds on blood glucose and lipid profiles in type 2 diabetic patients | |
| CN101277710B (zh) | 减肥组成物 | |
| RU2697670C9 (ru) | Фармацевтическая композиция, содержащая силибин и экстракт корня пуэрарии | |
| US20140127334A1 (en) | Drug compound for the control of blood glucose, blood lipids and weight | |
| KR20160007728A (ko) | 마늘껍질 추출물의 제조방법 및 이를 이용하여 제조된 당뇨 예방 및 개선용 식품 조성물 | |
| Patel et al. | Aphrodisiac activity of ethanolic extract of Pedalium murex Linn fruit | |
| EP2992933B1 (en) | Ginsenoside f2 for prophylaxis and treatment of liver disease | |
| CN112741851A (zh) | 低共熔溶剂法提取雀嘴茶提取物的方法及颗粒剂的制备和应用 | |
| CN110638996B (zh) | 一种促进胰岛再生降糖复合物及其制备方法和用途 | |
| WO2017129054A1 (zh) | 一种用于治疗尿毒症和尿蛋白的药物 | |
| CN110876768A (zh) | 一种减肥降脂和血脂的中药配方、制剂、制备方法及用途 | |
| CN101147584B (zh) | 预防和治疗糖尿病的保健食品及其制备方法 | |
| CN107537028B (zh) | 一种同时辅助降血糖及降血压的配方及其制备方法 | |
| CA2976896A1 (en) | Water extracts of cinnamon and radix astragali | |
| WO2019100843A1 (zh) | 一种浒苔多糖复合降血脂保健品及其制备方法 | |
| WO2015188428A1 (zh) | 一种应用于治疗代谢综合征的药物 | |
| CA3022247C (en) | Composition for treating diabetic disease | |
| KR20100111088A (ko) | 복합 생약 추출물을 유효성분으로 함유하는 당뇨병 또는 이로 인한 합병증의 예방 및 치료용 조성물 | |
| CN110420270A (zh) | 一种含有山茶油和鱼油的功能性组合物及其应用 | |
| CN104324278A (zh) | 一种减肥药及减肥冲剂的生产方法 | |
| JP2007051125A (ja) | 抽出物配合剤 | |
| CN107261079A (zh) | 龙虎人丹在制备预防和/或治疗糖尿病药物中的应用 | |
| KR101508561B1 (ko) | 귀리를 포함하는 혼합 생약재 추출물을 함유하는 당뇨병의 예방 또는 치료용 약학조성물 | |
| CN110404029B (zh) | 一种具有降血糖功效的组合物及其制备方法和应用 | |
| CN102552534B (zh) | 一种从明日草、豆豉和辣椒中提取降糖制剂的方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |